R&D and Product Overview
We specialize in the development of high-potential innovative biopharmaceutical solutions of non-monoclonal antibodies and specific dosage forms that require an advanced level of technological capabilities.
MD19 is used for the treatment of CDI, hemophilia A, and von Willebrand’s Disease (Type I). It is listed on the WHO Essential Medicines List, which recognizes it as an essential, effective, and safe drug for use in healthcare systems.
MD20 is a member of echinocandins whichis widely used as a broad-spectrum antifungal agent. It is recommended in the Clinical Practice Guideline for the Management of Candidiasis published by the Infectious Diseases Society of America (IDSA) as a treatment for neutropenic patients with weakened immune systems and non-neutropenic patients, as well as for non-neutropenic patients receiving empiric antifungal therapy. MD20 can effectively protect patients with acute myeloid leukemia who have impaired immunity from invasive fungal infections after the treatment of chemotherapy or hematopoietic stem cell transplantation, thus improving the success rate of these cancer therapies.
MD22 is in the triazole family of medications which widely used as a broad-spectrum antifungal agent. It has demonstrated great inhibitory effects against the major species of Candida. MD22 is recommended in the Practice Guidelines for the Diagnosis and Management of Aspergillosis published by the IDSA as a treatment or prophylaxis for confirmed invasive aspergillosis, and for the administration of empiric therapy.
MD23 is a suitable treatment for acromegaly patients whose conditions have failed to be controlled following surgery, radiotherapy, or therapy with dopamine agonists. It can alleviate their symptoms and reduce growth hormone and somatomedin-C levels in plasma, relieve conditions associated with gastroenteropancreatic neuroendocrine tumors, prevent complications after pancreatic surgery, and treat bleeding from gastroesophageal varices and prevent rebleeding.
MD21 is asynthetic nonapeptide analog of naturally occurring gonadotropin releasing hormone (GnRH or LH-RH) that acts as a potent inhibitor of gonadotropin secretion and leads to the suppression of steroid production in ovaries and testes. It is indicated for the palliative treatment of prostate cancer.
MD27 is an atypical antipsychotic with excellent efficacy. Compared to traditional antipsychotics, it features significantly lower incidence rates of extrapyramidal side effects such as tremors, rigidity, and movement disorder (Akathisia). It is indicated for the treatment of acute agitation associated with schizophrenia and bipolar I mania in adults.
HIV therapies worldwide have evolved. The traditional treatment strategy was to administer a combination of several single active ingredient drugs, but now it has shifted to taking combination drugs, which have benefits such as reduced side effects and greater ease of administration. This product is a new 505(b)2 drug developed in Taiwan, and it is prepared in the dosage form of bi-layer tablets to prevent possible interactions between active ingredients.
MD09 is a widely used antiepileptic drug It is indicated for adjunct therapy to treat seizures when oral administration of MD09 is temporarily not feasible or the patients with adverse drug reaction on other antiepileptic medicine. Studies have shown that treatment with MD09 would exist less side effect in both adults and children with.
MD13 is a type of norepinephrine that acts as a peripheral vasoconstrictor (alpha-adrenergic action), an inotropic stimulator of the heart, and a dilator of coronary arteries (beta-adrenergic action). It is an essential medication for emergencies.